CD8A and COVID-19: This includes the long-term maintenance of TRM and EM CD8+ T cells in COVID-19-convalescent lungs and increased IgA levels and IgA+ plasma cells in the lungs of COVID-19 convalescents, both at baseline and in response to SARS-CoV-2 peptides.